Objective: Acupoint herbal patching (AHP) is an external therapy of Traditional Chinese Medicine. This systematic review and metaanalysis sought to evaluate whether AHP during Sanfu Days has additional benefits in children with asthma.
Introduction
Pediatric asthma is the most prevalent chronic disease. [1] Approximately 1% to 37% of children suffer asthma in the world. [2] Global prevalence of asthma has increased exponentially in recent decades. [3, 4] Asthma is also a main cause of loss of school days and hospital visits for children. Pharmacologic interventions of asthma include the use of agents for control and relief. Despite advancement in medical care, pediatric asthma still leads to death and chance of recurrence in adulthood. [5] Inhaled corticosteroids and short-acting bronchodilators are most frequently administered to children with asthma. [6] However, growth suppression associated with corticosteroids use remains a big concern. [ 7] Persistent childhood asthma can even result in a decline in pulmonary function in young ages. [8, 9] Therefore, novel therapeutic approaches for pediatric asthma are unmet needs.
Complementary and alternative medicine is increasingly applied in children with asthma. [10, 11] Acupoint herbal patching (AHP) based on traditional Chinese Medicine (TCM) meridian theory has been widely used in China. [12] This non-invasive painfree approach can be accepted by children. "Treating Winter diseases in Summer" is a specific method of applying drugs on Sanfu Days to prevent and treat diseases attacks in winter. [13] This approach is firstly introduced in "Zhang's Treatise on General Medicine." Sanfu Days (each includes 10 days) is the hottest period within the year based on the lunar calendar. According to the theory of TCM, Sanfu Days are recognized as the richest time for Yang-Qi. Application of AHP during Sanfu Days generates curative effects through transdermal absorption of herbs, acupoint stimulation, and time effect. A number of clinical trials [14] [15] [16] [17] [18] have evaluated the additional beneficial effects of AHP during the Sanfu Days for treating pediatric asthma. However, the beneficial effects of AHP on the pulmonary function are still controversial. [19, 20] A well-designed meta-analysis [21] indicated that AHP had favorable immunomodulatory effects for pediatric asthma. However, clinical outcomes and lung function were not evaluated in this meta-analysis. Another previous meta-analysis [22] only investigated the effects of AHP during Sanfu Days for stable asthma. No previous meta-analysis has investigated the add-on effects of AHP in childhood asthma during Sanfu Days. Therefore, we performed this systematic review and metaanalysis to investigate the add-on effects of AHP during Sanfu Days on the pulmonary function and acute disease attack of childhood asthma.
Materials and methods

Data source and literature search
This meta-analysis strictly followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Metaanalyses Statement. [23] We comprehensively searched the Cochrane Library, PubMed, Embase, CNKI, VIP, and WanFang databases from their inception to March 2019. We used the following keywords for searching in English databases: "Sanfutie" OR "acupoint" AND "asthma" AND "children" OR "childhood" OR "pediatric." For the Chinese databases, "san fu" OR "Dong bing xia zhi" OR "Tie fu" AND "xue wei" AND "xiao chuan" AND "er tong" OR "xiao er" AND "sui ji" AND "dui zhao" were applied in combination. Reference lists of eligible trials were manually scanned to identify any possible missing trials. Ethical approval was not needed due to this study only analyzed the available articles.
Study selection
Inclusion criteria were:
1. study design: randomized controlled trials (RCT); 2. study population: children ( 14 years old) with asthma; 3. interventions: AHP plus Western medicine compared with the same Western medicine alone during Sanfu Days; and 4. primary outcome was the frequency of acute asthma attack and secondary outcomes were the relapse of asthma, peak expiratory flow (PEF), forced expired volume in 1 s (FEV1), and adverse events.
Exclusion criteria were as follow:
1. participants did not restrict in children population; 2. AHP combined other Chinese herbal preparation as intervention; 3. AHP did not apply during the Sanfu Days; 4. follow-up duration <3 months for the remission stage of asthma; and 5. retrospective studies, self-controlled trial, dissertation, or duplicate publication.
Data extraction and risk of bias assessment
Two authors independently abstracted data and evaluated the methodological quality of all eligible trials. Discrepancy was resolved by consensus. We recorded the surname of the first author, publication year, sample size, age at baseline, aspects of methodological assessment, AHP intervention (including herbs, acupoint, and course of treatment),control intervention, length of follow up, and outcome measures. The Cochrane risk bias tool was used to examine the methodological quality of the included RCT. Each domain was grouped as "unclear risk of bias," "low risk of bias" or "high risk of bias."
Data analysis
Meta-analysis was conducted using RevMan 5.2 software and the STATA 12.0. Continuous data were presented as mean difference (MD) or standardized mean differences [SMD] with 95% confidence interval (CI). Dichotomous data were presented as risk ratio (RR) with 95% CI. Heterogeneity between trials was tested using the I 2 statistic and the Cochrane Q test. Due to presence of obviously clinical heterogeneity, we selected a random effect model for all the analyses. Subgroup analyses were scheduled by the stage of asthma. Publication bias assessment by the Begg's test [24] and Egger's test [25] was planned if the outcome included more than five trials. Sensitivity analyses were conducted by removal of any single trial at each turn.
Results
Literature search
Briefly, 539 articles were identified in our initial literature search.
After removal of duplicates, 245 articles remained. Of which, 188 articles were removed after scanning the titles and abstracts. The remaining 57 articles were retrieved for full-text assessment. Forty-six articles were further removed mainly due to the lack of interesting outcomes, inappropriate intervention, acupoint application versus Western medicine or self-controlled trials. Finally, 11 trials [14] [15] [16] [17] [18] [19] [20] [26] [27] [28] [29] were included in this meta-analysis. Figure 1 shows the flow chart of trial selection process. Table 1 presents the basic characteristics of these eligible trials.
Study characteristics
The included trials were conducted in China and published between 2003 and 2018. Sample size ranged from 26 to 160, with a total of 882 children. Seven trials [15, 16, [18] [19] [20] 26, 27] enrolled the children in remission and four trials [14, 17, 28, 29] recruited the children with all stage of asthma. Western pharmacological medications included glucocorticoid, seretide, montelukast, budesonide, and salbutamol. The length of follow-up ranged between 1 month and 2 years. AHP was administered between 3 and 9 times during a period of 30 to 40 days. Table 2 describes the details of acupoint sticking therapy.
Risk of bias
Two trials [17, 22, 27, 30] reported the detailed method of random and others only claimed randomized controlled designs. Dropout and sample size calculation was not mentioned in the included trials. Overall, included trials had unclear risk of bias (supplemental Table S1 , http://links.lww.com/MD/D702). [19] Remission 80/80 5-14 AHP + inhale seretide Inhale seretide 12 Frequency of acute attack, FEV1 Wu Y 2014 [15] Remission 43/43 3-12 AHP + inhale glucocorticoid Inhale glucocorticoid 12 Frequency of acute attack Zhao J 2015 [16] Remission 20/20 2-12 AHP + inhale glucocorticoid Inhale glucocorticoid 12 Frequency of acute attack + AE Wang XY 2016 [17] All stage 33/31 6-10 AHP + Montelukast Montelukast 3 FEV1, PEF, AE Wu QL 2016 [18] Remission 31/25 5-14 AHP + Montelukast Montelukast 9 FEV1, PEF Yin XL 2017 [26] Remission 40/40 5-12 AHP + inhale glucocorticoid Inhale glucocorticoid 12 Relapse, AE Zhou F 2017 [27] Remission 44/42 6-9 AHP + inhale budesonide Inhale budesonide 12 Frequency of acute attack Fu YL 2017 [20] Remission 60/60 4.6-12.4 AHP + Montelukast/seretide Montelukast/seretide 24 Frequency of acute attack,FEV1, PEF Shu YF 2017 [28] All stage 40/40 3-11 AHP + inhale budesonide Inhale budesonide NP FEV1, PEF Zhao XB 2018 [29] All stage 74/74 2-13 AHP + Budesonide + Salbutamol Budesonide + Salbutamol 12 Relapse, FEV1, PEF AE = adverse events, AHP = acupoint herbal patching, FEV1 = forced expiratory volume in one second, NP = not provided, PEF = peak expiratory flow.
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Frequency of acute attack and asthma relapse
Five trials [15, 16, 19, 20, 27] reported the effect of AHP on the frequency of acute asthma attack. Meta-analysis indicated that AHP significantly reduced the frequency of acute asthma attack (MD À1.62; times/year; 95% CI À2.13 to À1.11; I 2 = 76%, P = .003) in a random effect model (Fig. 2) . Two trials [22, 26] reported the effect of AHP on the asthma relapse. A random effect model meta-analysis showed that AHP had no clear effect on the relapse of asthma (RR 0.25; 95% CI 0.05-1.19; I 2 = 50%, P = .16; Fig. 3 ).
Pulmonary function indexes
Six trials [17] [18] [19] [20] 28, 29] reported the effect of AHP on FEV1. As shown in Figure 4 , there was no significant heterogeneity between trials (I 2 = 18%, P = .30). Meta-analysis showed that AHP [19] White Mustard Seed, Rhizoma Corydalis, Radix Kansui, Herba Asari Feishu (BL 13), Dazhui (GV 14), Dashu (BL11), Pishu (BL 20)
3-4 h/9 d sessions during dog days Wu Y 2014 [15] White Mustard Seed, Rhizoma Corydalis, Radix Kansui, Herba Asari Feishu (BL 13), Xinshu (BL 15), Geshu (BL 17)
2-4 h/9 d sessions before, during and after dog days Zhao J 2015 [16] White Mustard Seed Feishu (BL 13) 30 min-2 h/9 d sessions in dog days Wang XY 2016 [17] White 1-4 h/9 d sessions during dog days Shu YF 2017 [28] White Mustard Seed, Rhizoma Corydalis, Radix Kansui, Herba Asari Feishu (BL 13), Xinshu (BL 15), Geshu (BL 17)
1-3 h/9 sessions during dog days Zhao XB 2018 [29] White Mustard Seed, Rhizoma Corydalis, Cortex Cinnamomi, Radix Kansui, Herba Asari, Rhizoma Pinelliae (Fig. 4) . Subgroup analyses showed a stronger effect of AHP on FEV1 in the all stage asthma (SMD 0.63; 95% CI 0.39-0.86) than those in remission stage (SMD 0.36; 95% CI 0.14-0.57). The effect of AHP on PEF was reported in six trials. [14, 17, 18, 20, 28, 29] Meta-analysis indicated that AHP significantly reduced the PEF (SMD 0.61; 95% CI 0.39-0.82; I 2 = 24%, P = .25; Fig. 5 ). Also, a stronger effect of AHP on PEF was noted in the all stage asthma (SMD 0.71; 95% CI 0.47-0.95) than remission subgroup (SMD 0.45; 95% CI 0.11-0.80).
Adverse events
Three trials [16, 17, 26] reported the adverse events as an outcome. The most common adverse events associated with AHP were local skin redness, itching, stinging, and blistering. The incidence of total skin adverse events in the AHP group was 16.1%. Nevertheless, all the adverse events were mild and without reporting serious adverse effects.
Sensitivity analysis and publication bias
Sensitivity analysis showed that any single trial did not significantly alter the pooling effect sizes (data not shown).
Results of the Begg's test (P = .260) and Egger's test (P = .558) revealed no evidence of publication bias for FEV1 outcome. Also, publication bias was not found for PEF outcome based on the results of Begg's test (P = 1.000) and Egger's test (P = .588).
Discussion
This systematic review and meta-analysis suggest that adjunctive treatment with AHP during Sanfu Days achieves additional beneficial effects in reducing the frequency of acute attack and improving pulmonary function in terms of FEV1 and PEF in children with asthma. Local skin reactions induced by AHP were frequently developed. However, these adverse effects were generally mild and spontaneously recovered.
Our findings are consistent with those in previous systematic review and meta-analysis. [22, 31, 32] AHP adding to Western medicine had additional benefits on improving pulmonary www.md-journal.com function in patients with asthma. In pediatric asthma patients, AHP could regulate serum levels of immunoglobulin (Ig) A, Ig E, Ig G, interleukin-4, and interferon-g. [21] However, use of AHP was not restricted to Sanfu Days and time effect of AHP was not considered. [18] White Mustard Seed, Radix Kansui, and Rhizoma Corydalis are frequently selected herbs in the preparation of acupoint application. The Feishu (BL 13), Danzhong (CV 17), Geshu (BL 17), and Tiantu (CV22) should be considered as the key acupoints. Importantly, selection of herbs and acupoints should be considered the TCM syndrome differentiation. Future trials should focus on the comparison between different herbal preparations and various stimulating acupoints. Also, comparison between Sanfu Days and any time treatment will be a meaningful topic for future trials.
Our systematic review and meta-analysis indicated that AHP adding to Western medicine could reduce 1.62 times/year of frequency of acute attack than the Western medicine alone. AHP also regulated the serum levels of Ig A, [26, 27] Ig E, [26, 27] Ig G, [26] CD4 + T-lymphocytes, [29] CD8 + T-lymphocytes, [29] and eosinophil. [26, 30] However, there was no evidence to support the beneficial effects of AHP on the relapse of asthma in our metaanalysis. This result may be explained by relatively short duration of follow-up. Asthma is a chronic inflammatory disease. Besides the immunomodulatory effects, AHP could reduce serum levels of tumor necrosis factor-a, interleukin-6, and high-sensitivity Creactive protein. [28] Anti-inflammatory and immunomodulatory effects of AHP may partly account for its beneficial effects.
An important concern was the skin reaction such as local skin redness, itching, burning, pain, and even cause blisters. However, treatment induced blisters appeared to exhibit better therapeutic effect. [18] This phenomenon may be explained by local infiltrative effect make it easier for the body to absorb the herbs through the acupoints. Importantly, children with skin allergies or damaged skin should be treated with caution.
There are several limitations in this meta-analysis. First, main methodological flaws of the included trials were lack of description of randomization and allocation concealment method. Second, lack of TCM syndrome differentiation in recruiting patients may be another potential limitation. Third, relapse of asthma as an outcome was potentially unreliable due to the relatively short follow-up period. Future trials with longer follow-up duration are required to investigate AHP on asthma relapse. Fourth, there was highly heterogeneous I 2 in pooling the frequency of acute attack outcome. This results should be interpreted with caution due to a random-effect meta-analysis may have led to over-and under-estimate the effect of AHP. Moreover, highly clinical heterogeneity existed in the acupuncture points and constituent of herbs, which makes it difficult to determine what specific intervention component exert the noted effect. Fifth, different primary pharmacological medications are obviously clinical heterogeneity of the original trials. However, the limited number of trials in each outcome prevented us to perform the subgroup analysis by different primary pharmacological medications. Finally, results of publication bias may be unreliable due to the number of included trials was less than the recommended arbitrary number of 10. [33] Our meta-analysis provided limited evidence for the benefits of AHP in children with asthma. For children with frequent attack of asthma, adjunctive treatment with AHP may achieve additional beneficial effects. Furthermore, AHP also exhibited promising effects in improving lung function of childhood asthma. However, an optimal AHP intervention should be determined in future trials.
Conclusions
AHP adding to Western medicine during Sanfu Days has additional beneficial effects in reducing the frequency of acute attack and improving pulmonary function indexes in pediatric asthma. However, the current findings should be interpreted with caution owing to the methodological flaws of the analyzed trials.
